Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sweden Tackles Regulatory Barriers To Decentralized Trials

MPA Offers Free Advice On The Dos And Don’ts Of Virtual Trials

Executive Summary

The COVID-19 pandemic has given a new impetus to Sweden’s ongoing efforts to support decentralized clinical trials. 

You may also be interested in...



EU Decentralized Trials Guide Due Early In 2022

The upcoming EU guideline on decentralized clinical trials is the result of a “learning by doing” exercise and builds on various pilots and initiatives launched by different member states.

Embracing Decentralized Trials Is Not ‘Plug And Play’

Trial sponsors are proactively seeking opportunities to incorporate decentralized elements into their studies, but the lack of regulatory guidance makes it a difficult exercise.

Industry Is Moving Fast With Decentralized Trials, But Is It Too Fast?

Companies like Bayer and AstraZeneca are seeing what a difference decentralization makes as CVS is rapidly expanding its clinical research business.

Related Content

Topics

UsernamePublicRestriction

Register

PS145139

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel